1233518-55-2

Upstream product

• 50397-74-5 2-bromo-4-cyanoaniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 1233518-58-5 Ethyl 8-bromo-4-[(3-chloro-4-methoxybenzyl)amino]-6-cyanoquinoline-3-carboxylate 
• 1233518-59-6 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-cyclopropylquinoline-3-carboxylate 
• 1233518-61-0 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(N,N-dimethylamino)quinoline-3-carboxylate 
• 1426161-88-7 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(N,N-dimethylethane-1,2-diamino)quinoline-3-carboxylate 
• 1426161-91-2 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(ethylamino)quinoline-3-carboxylate 
• 1426161-94-5 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(N-cyclopropylamino) quinoline-3-carboxylate 
• 1426161-96-7 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(morpholin-4-yl)quinoline-3-carboxylate 
• 1233518-60-9 4-(3-chloro-4-methoxybenzylamino)-8-cyclopropyl-3-(hydroxymethyl)-quinoline-6-carbonitrile 
• 1233518-62-1 C₂₁H₂₁ClN₄O₂ 
• 1233518-72-3 C₂₃H₂₆ClN₅O₂ 
• 1426162-01-7 C₂₁H₂₁ClN₄O₂ 
• 1233518-75-6 C₂₂H₂₁ClN₄O₂ 
• 1233518-77-8 C₂₃H₂₃ClN₄O₃ 

Relevant academic research and scientific papers

Phosphodiesterase inhibitors and uses thereof

The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.

Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease

Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain. Recent studies have demonstrated the importance of the nitric oxide/cGMP/cAMP-responsive element-binding protein (CREB) pathway to the process of learning and memory. Thus, PDE5 inhibitors (PDE5Is) are thought to be promising new therapeutic agents for the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss. To explore this possibility, a series of quinoline derivatives were synthesized and evaluated. We found that compound 7a selectively inhibits PDE5 with an IC50 of 0.27 nM and readily crosses the blood brain barrier. In an in vivo mouse model of AD, compound 7a rescues synaptic and memory defects. Quinoline-based, CNS-permeant PDE5Is have potential for AD therapeutic development.